Stock Monitor: BioSpecifics Technologies Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on Vericel Corp. (NASDAQ: VCEL). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VCEL as the Company's latest news hit the wire. On March 23, 2018, the Company announced that the data from the Phase-3 SUMMIT Extension Study, evaluating MACI® in patients with knee injury and Osteoarthritis Outcome Score (KOOS) pain, was published in the American Journal of Sports Medicine. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for BioSpecifics Technologies Corp. (NASDAQ: BSTC), which also belongs to the Healthcare sector as the Company Vericel. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=BSTC

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Vericel most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=VCEL

Sustained Improvement in KOOS Pain and Function for Study Period was Observed in SUMMIT Extension Study

The SUMMIT Extension Study was a three-year follow-up of the SUMMIT clinical trial, entailing up to five years of observation after surgery. Of the 144 patients randomized in the SUMMIT study, 89% continued observation out to five years in the extension study. Evaluation of these patients post treatment showed that there was sustained improvement in both KOOS pain and function for the study period. A post?hoc evaluation showed that the significantly greater improvement of MACI® versus microfracture observed at the two-year endpoint was maintained at the five-year follow-up. The frequency of adverse events and subsequent surgical procedures were similar in both the MACI® and microfracture treatment groups. The Extension Study is the first study in the field of cartilage repair to provide long-term, five-year follow-up results from a successful multicenter, superiority study in comparison to microfracture.

FDA Approved MACI® for Treatment of Symptomatic Cartilage Defects of the Knee in Adults

In December 2016, the US Food and Drug Administration (FDA) approved MACI® for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. MACI® is the first FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The FDA approval was based on the results of the SUMMIT study, a Phase-3, prospective, multicenter, randomized, controlled study that enrolled a total of 144 patients. The co-primary efficacy endpoint was the change from baseline to two years in the KOOS pain and function scores. The SUMMIT study is the only Phase-3 clinical trial of a cartilage repair product to date to demonstrate statistically significant improvement over microfracture at both one and two years.

About Articular Cartilage Lesions

Articular cartilage lesions are a collective term for injuries where the articular cartilage of the knee joint is affected. Articular cartilage is a highly organized avascular tissue composed of chondrocytes. Its primary function is to enable the smooth articulation of joint surfaces, and to cushion compressive, tensile and shearing forces. Articular cartilage lesions are caused by both acute and repetitive trauma resulting in knee pain, effusion or mechanical symptoms, and is common in patients of varying ages. Articular cartilage lesions have a poor capacity for intrinsic repair. If left untreated, Articular cartilage lesions may progress to debilitating joint pain, dysfunction, and osteoarthritis.

About MACI®

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellular scaffold product indicated for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. The MACI implant consists of autologous cultured chondrocytes seeded onto a resorbable Type-I/III collagen membrane. Autologous cultured chondrocytes are human-derived cells which are obtained from the patient's own cartilage for the manufacture of MACI®. Effectiveness of MACI® in joints other than the knee has not been established.

About Vericel Corp.

Founded in 1989 and is headquartered in Cambridge, Massachusetts, Vericel is a commercial-stage biopharmaceutical company, developing, manufacturing, and marketing autologous cell-based therapies for patients with serious diseases and conditions. The Company markets two cell therapy products in the United States, MACI®, and Epicel®.

Stock Performance Snapshot

March 26, 2018 - At Monday's closing bell, Vericel's stock was slightly up 0.99%, ending the trading session at $10.20.

Volume traded for the day: 776.60 thousand shares.

Stock performance in the last month ? up 39.73%; previous three-month period ? up 108.16%; past twelve-month period ? up 257.89%; and year-to-date - up 87.16%

After yesterday's close, Vericel's market cap was at $373.63 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.9% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors